The World Health Organization issued warnings on falsified semaglutides used in diabetes and weight-loss drugs in light of three altered batches of products detected in Brazil, the UK and the U.S.

Semaglutide is the active ingredient used in Novo Nordisk's diabetes drug Ozempic and weight-loss treatment Wegovy.

The WHO has observed an increase in reports since 2022. The notice was the first official issuance by the agency following confirmation of reports. The agency also noted increased demand for the medications.

Falsified products could be harmful and if they do not have the necessary raw components, they can lead to health complications resulting from unmanaged blood glucose levels or weight, the WHO said.